Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
about
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare CostsMapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gainsEconomic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
P2860
Q28547963-B992408B-4EBF-4DDB-899E-DB7D005E8C52Q33557934-FDB0D93E-32DD-4B33-8794-CBF275FCD4E2Q35226107-83F9B1DE-1E86-4B03-8103-153D744998FFQ35524382-3F010592-3C16-43FF-8B18-9EA5AE8B3479Q36768997-23E7A1FE-8E30-4952-B14A-581D48CA71CFQ38530066-AF86CF9E-DABB-40FF-B378-9C2E0BE9DF97Q38749573-F8DDCCC6-E6E3-405B-A7B7-E1017782D02DQ38776967-23F2D694-7E47-4FCE-A8FB-30F898A40AACQ38786919-62192925-8E73-48A1-BDA0-0B62E0A05A2CQ39737036-5624ED42-2997-460F-B29E-0754815ED03EQ41042198-0B985E29-A808-4956-9C9A-CB81FECCD112Q52564578-B483AF51-6F60-4C3C-931A-D9177583069A
P2860
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Lenalidomide for multiple myel ...... therapy in England and Wales.
@en
Lenalidomide for multiple myel ...... therapy in England and Wales.
@nl
type
label
Lenalidomide for multiple myel ...... therapy in England and Wales.
@en
Lenalidomide for multiple myel ...... therapy in England and Wales.
@nl
prefLabel
Lenalidomide for multiple myel ...... therapy in England and Wales.
@en
Lenalidomide for multiple myel ...... therapy in England and Wales.
@nl
P2093
P2860
P1476
Lenalidomide for multiple myel ...... therapy in England and Wales.
@en
P2093
Ruth E Brown
Sean Stern
Steve Schey
Sujith Dhanasiri
P2860
P2888
P304
P356
10.1007/S10198-012-0395-6
P577
2012-05-10T00:00:00Z